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Abstract
Purpose: Patients with severe community-acquired pneumonia (CAP) are believed to have an exaggerated inflammatory response to bacterial infection. Therapies aiming to modulate the inflammatory response have been largely unsuccessful, perhaps reflecting that CAP is a heterogeneous
disorder that cannot be modulated by a single anti-inflammatory approach. We hypothesize that
the host inflammatory response to pneumonia may be characterized by distinct cytokine patterns,
which can be harnessed for personalized therapies.
Methods: Here, we use hierarchical cluster analysis of cytokines to examine if patterns of inflammatory response in 13 hospitalized patients with CAP can be defined. This was a secondary data
analysis of the Community-Acquired Pneumonia Inflammatory Study Group (CAPISG) database.
The following cytokines were measured in plasma and sputum on the day of admission: interleukin (IL)-1β , IL-1 receptor antagonist (IL-1ra), IL-6, CXCL8 (IL-8), IL-10, IL-12p40, IL-17, interferon (IFN)γ, tumor necrosis factor (TNF)α, and CXCL10 (IP-10). Hierarchical agglomerative
clustering algorithms were used to evaluate clusters of patients within plasma and sputum cytokine determinations.
Results: A total of thirteen patients were included in this pilot study. Cluster analysis identified distinct inflammatory response patterns of cytokines in the plasma, sputum, and the ratio of
plasma to sputum.
Conclusions: Inflammatory response patterns in plasma and sputum can be identified in hospitalized patients with CAP. Characterization of the local and systemic inflammatory response
may help to better discriminate patients for enrollment into clinical trials of immunomodulatory
therapies.

1

Introduction

Even with appropriate antibiotic therapy, some hospitalized patients with community-acquired pneumonia (CAP) progress to
clinical failure and death. High cytokine levels produce an exaggerated inflammatory response, known as the cytokine storm, and
may drive poor clinical outcomes. As a result, investigators have
evaluated the use of immunomodulatory agents in an attempt
to control this exaggerated inflammatory response and reduce
patient mortality. Corticosteroids are the primary immunomodulatory agents considered for patients with CAP, and results of
several investigations 1–10 have been evaluated in recent system-
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atic reviews and meta-analyses 11,12 Although steroids are considered important immunomodulatory agents for these patients,
other considerations include macrolides 13–18 statins 19–29 and tissue factor pathway inhibitor 30 .
Severe pneumonia at the time of hospital admission is the primary
criterion for patient enrollment into clinical trials of immunomodulatory therapies 10,31 . This is due to a general consensus that
severity of disease and the inflammatory response are positively
correlated. If this is the case, patients with more severe pneumonia should present with an exaggerated inflammatory response
and would be ideal candidates for enrollment into trials of immunomodulatory therapies. Although this inflammation-severity
correlation may be true at the population level, increased disease
severity at the individual level may also be impacted by factors
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unrelated to the inflammatory response. For example, a patient
hospitalized with CAP with a prior history of congestive heart failure who develops severe respiratory deterioration due to cardiogenic pulmonary edema may not have an exaggerated inflammatory response. Any patient without an exaggerated inflammatory
response, regardless of disease severity, would not be an appropriate candidate for a trial of an immunomodulatory therapy. Several experts in the field have indicated that the failure of many
recent investigations into immunomodulation in hospitalized patients with CAP is likely to be related to our inability to properly
characterize the patients who would benefit from these therapies
prior to enrollment 32,33 . To address this concern, methods to
better identify patients with and without an exaggerated inflammatory response are needed. We hypothesize that patients with
CAP can be clustered into distinct inflammatory response groups
at the time of hospital admission using cytokine levels in plasma
and/or sputum.
The objective of this study was to evaluate the utility of hierarchical agglomerative cluster analysis of plasma and sputum cytokines to examine if inflammatory patterns can be defined in
hospitalized patients with CAP.

2
2.1

Methods
Study design and setting

This was a secondary data analysis of data previously collected from the Community-Acquired Pneumonia Inflammatory
Study Group (CAPISG). An in-depth description of the CAPISG
study and specimen collection has been previously published 34 .
Briefly, we prospectively enrolled non-consecutive adult patients
hospitalized with CAP at the University of Louisville Hospital,
Louisville, Kentucky, USA, from 01 April 2011 to 01 August 2012.
The study protocol required enrolled patients to provide blood
and sputum specimens on the day of admission and at regular
intervals during hospitalization.
2.2

Study population

Adult patients with CAP in whom both blood and sputum specimens were obtained on the day of admission were included in
the current pilot study. CAP was defined as a new pulmonary
infiltrate (within 24 hours of admission), associated with at least
one of the following criteria: a new or increased cough, an abnormal temperature (<35.8 ◦ C or >37.8 ◦ C), or an abnormal leukocyte count (leukocytosis, leukopenia or the presence of immature
neutrophils). Pneumonia was defined as community-acquired if a
patient had no history of hospitalization during the 2 weeks prior
to admission. Patients were excluded if they had a medical history
that, in the investigator’s opinion, precluded subject compliance
with the protocol.
2.3

Data sources and measurements

After patient consent, trained study coordinators and/or research
associates collected clinical data from the patient’s medical record
onto a paper case report form. A separate research associate entered these data into a secure, web-based data management sys-

tem hosted by the University of Louisville Division of Infectious
Diseases. Data quality issues identified by the research associate
entering the data were fixed prior to submission of the case to
the database. The database also contains several data quality
checks to limit out-of-range errors and inappropriate data types.
These data quality structures were built in based on our decades
of experience collecting and entering clinical data into electronic
databases. After all data queries were resolved, the case was accepted into the database for analysis. The following clinical variables were collected and evaluated:
1. Demographics: age and sex
2. Comorbid conditions: chronic obstructive pulmonary disease (COPD), cerebrovascular disease, congestive heart failure, chronic renal disease, diabetes mellitus, active coronary artery disease, neoplastic disease, neurologic disease/mental illness, acute renal disease, hyperlipidemia,
HIV status, ACE inhibitor use, aspirin use, beta blocker use,
heparin use, statin use, hospitalization for 2 or more days
in the prior 90 days, home infusion therapy, home oxygen
therapy, nursing home resident, and atrial fibrillation.
3. Physical examination: oral temperature, heart rate, respiratory rate, systolic blood pressure, and diastolic blood pressure.
4. Laboratory tests: pH, FiO2 , PaCO2 , serum bicarbonate,
serum blood urea nitrogen (BUN), serum creatinine, serum
glucose, hematocrit, hemoglobin, serum potassium, serum
sodium, platelet count, procalcitonin, and white blood cell
count (WBC).
5. Severity of CAP: need for ICU admission on arrival, altered
mental status, vasopressors, IV steroids on admission, and
the Pneumonia Severity Index.
All microbiological evaluations were done according to clinical
needs per hospital microbiology protocols.
2.4 Specimen collection and processing
2.4.1 Plasma
Blood samples were obtained on the day of admission to the
hospital. Venous blood was collected using sodium citrate BD
Vacutainer R tubes and processed within 2 hours of collection.
The tubes were centrifuged at 300 × g for 10 minutes and the
plasma separated by aspiration, aliquoted (0.5 ml each) and
stored frozen at -80 ◦ C until assayed.
2.4.2

Sputum

Sputum samples were obtained on the day of admission to the
hospital and processed within 2 hours of collection, according
to the method described by Pizzichini et al. 35 . Briefly, samples
were diluted with an equal amount of a 0.1% Dithiothreitol solution in phosphate buffered saline (PB and incubated in a rocking
platform for 15 minutes in order to digest the mucus. An equal
volume of sterile saline was added, followed by an additional 5
minutes of incubation. The samples were then filtered through
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Table 1 Patient Characteristics

Variable
Sex
Age (years)
Obese (BMI>30 kg/M2)
Immunocompromized
ICU admission
Nursing home resident
Active cancer
Liver disease
Renal disease
Congestive heart failure
Cerebrovascular disease
Altered mental status
Heart rate, (beats/min)
Respiratory rate breaths/min
Systolic blood pressure (mmHg)
Oral temperature (F)
Hematocrit (%)
Blood urea nitrogen mg/dl
Sodium mmol/litre
Arterial pH
PaO2 mmHg
Glucose mg/dl
Pleural effusion
Pneumonia Severity Index risk class
Days to clinical stability
Culture positive
Length of stay (days)
In-hospital mortality

Patient Identification Number
1
2
3
Male
Female
Male
78
54
40
No
Yes
No
No
No
Yes
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
91
130
98
18
22
24
95
144
114
99
100
100
41.4
48.8
38
13
16
13
137
134
140
No ABG
7.36
No ABG
No ABG
59
No ABG
116
97
101
No
Yes
No
Class III
Class III
Class I
2
2
7
Yes
Yes
Yes
3
4
8
No
No
No

4
Female
51
Yes
Yes
No
No
No
No
No
Yes
No
No
78
16
135
98.7
40.3
22
133
7.46
60
295
No
Class II
2
Yes
3
No

5
Male
63
No
No
No
No
No
No
Yes
No
No
No
93
22
99
100.4
42.5
36
133
No ABG
No ABG
88
No
Class IV
3
No
3
No

nylon gauze and centrifuged at 790 × g for 10 minutes. The cellfree supernatants were aliquoted and stored frozen at -80 ◦ C until
used for the measurement of cytokine levels.
2.5

Cytokine measurements

Laboratory methods for cytokine measurements have been previously published 34 . The concentrations of interleukin (IL)-1β ,
IL-1 receptor antagonist (IL-1ra), IL-6, CXCL8 (IL-8), IL-10, IL12p40, IL-17, interferon (IFN)γ, tumor necrosis factor (TNF)α,
and CXCL10 (IP-10) in plasma and sputum samples were determined using Milliplex MAP Multiplex kits (EMD Millipore, Billerica, MA). Following thawing, plasma and processed sputum samples were centrifuged at 10, 000×g for 5 min and the supernatants
used in the assay according to the manufacturer’s instructions
2.6

Compliance with Ethical Standards

The University of Louisville Human Subjects Program Protection
Office approved this study prior to any data collection (approval
number: 07.0182). Informed consent was obtained from all individual participants included in the study.
2.7

Statistical analysis

For each patient, cytokine values were scaled by subtracting the
mean cytokine value across all patients from each particular patient cytokine level. This value was then divided by the standard deviation of the particular cytokine. The scale function in
Rv3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) was used for scaling purposes. Hierarchical agglomerative
clustering algorithms were then used to evaluate clusters of patients within the plasma and sputum determinations separately.
Finally, the plasma determination was divided by the sputum determination and the same clustering methods were used to evaluate clusters from the plasma/sputum ratio. Ensemble cluster-

6
Male
62
No
Yes
No
No
Yes
No
No
No
No
No
87
20
115
98.6
35
40
129
7.41
67
102
No
Class V
Unknown
Yes
15
Yes

7
Female
72
Yes
Yes
No
No
Yes
No
No
Yes
No
No
118
28
187
102
34
10
140
No ABG
No ABG
105
No
Class IV
4
No
6
No

8
Female
57
Yes
No
No
Yes
No
No
No
Yes
Yes
No
108
24
166
101
43.5
31
133
7.39
94
185
Yes
Class IV
6
No
6
No

9
Female
53
No
Yes
Yes
No
No
No
No
No
No
No
77
28
185
101
36.1
5
140
7.44
66
107
No
Class II
4
No
6
No

10
Male
78
No
Yes
No
No
Yes
No
No
Yes
No
Yes
94
20
133
99.2
31.8
70
146
No ABG
No ABG
108
No
Class V
2
No
6
No

11
Male
85
No
No
Yes
No
No
No
No
No
Yes
No
156
40
99
100
43.2
21
140
7.41
78.4
179
Yes
Class V
6
No
6
No

12
Male
65
No
Yes
No
No
No
No
No
No
No
No
92
25
151
97.5
34.2
10
139
7.414
65.9
111
No
Class II
2
Yes
2
No

13
Male
59
No
Yes
Yes
Yes
No
No
No
No
No
No
102
25
90
98
37.7
13
138
No ABG
No ABG
174
Yes
Class III
3
No
9
Yes

ing methods were used to identify the most appropriate distance
metric and cluster linkage function for hierarchical agglomerative
cluster analysis 36 . From these results, the distance metric and
linkage function providing the most clinically meaningful clustering were chosen. For each clustering algorithm, dendrograms
and heatmaps were created to visualize the clusters and scaled
cytokine values. Dark blue colors on the heatmaps represent high
cytokine values, white colors represent average values, and dark
red represent low values. To compare plasma and sputum clustering dendrograms, we used the Pearson cophenetic correlation
statistic. Briefly, cophenetic correlation statistics are similar to
traditional correlation measures, ranging from -1 (perfect negative correlation) to +1 (perfect positive correlation), with a zero
being no correlation.
To compare differences in patient characteristics between groups
defined as having a higher inflammatory response versus a lower
inflammatory response from the cluster analysis, frequencies and
percentages for categorical variables and medians with interquartile ranges were presented for continuous variables. Statistical
hypothesis testing was not done due to the probability of error
in the multiple tests and the limited number of patients included
in the study. R v3.2.0 (R Foundation for Statistical Computing,
Austria) was used for all analyses. The following R packages and
were used: gplots 37 , dendextend 38 , dendextendRcpp 39 , clue 36 ,
and RColorBrewer 40 .

3
3.1

Results
Demographic, clinical and laboratory findings

A total of 13 patients were included in this pilot study. Baseline
patient characteristics and clinical outcomes for each of the 13
patients can be found in Table 1. No patients were started on vasopressors on admission or during hospitalization. For higher vs
lower inflammatory phenotype groups identified via cluster analULJRI Vol 1,(1) 2017
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Fig. 1 Heatmaps and dendrograms for cytokines in sputum and plasma. Each heatmap and dendrogram depict some separation of patients’
inflammatory response. The cophenetic correlation coefficient comparing the clustering of patients in plasma and sputum determinations was 0.14,
suggesting low correlation between plasma and sputum clusterings. a horizontal line was drawn to indicate a suggested separation of inflammatory
response patterns based on the cluster dendrograms and visual inspection of the heatmaps.
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ysis of the sputum specimens patients with a higher inflammatory
phenotype had a lower rate of ICU admission (0% vs 67%, respectively). Similarly, when evaluating plasma cytokine profiles,
patients with a higher inflammatory phenotype had a lower rate
of ICU admission versus those with a lower inflammatory phenotype (12% vs 60%, respectively). This difference did not remain
when evaluating the plasma/sputum ratio. No other clinically
meaningful differences were identified.

an interaction of the invading pathogen with cells of the innate
immune system. The identification of the pathogen is made by
receptors called pattern recognition receptors (PRR). Streptococcus pneumoniae, as well as other extracellular pathogens may
be recognized by a family of membrane-bound PRPs called Tolllike receptors. Influenza and other intracellular pathogens may
be recognized by a family of cytoplasmic PRPs called NOD-like
receptors.

A pathogen was identified in 6 of the 13 patients. Streptococcus
pneumoniae was identified in patients 1, 4, and 12, influenza in
patient 2, Pseudomonas aeruginosa in patient 3, and methicillinresistant Staphylococcus aureus in patient 6.

During the initial 24 hours after infection, activation of theses receptors will trigger synthesis and secretion of cytokines. Since different pathogens are recognized by different receptors with different signaling mechanisms, it is predictable that the initial inflammatory response may be pathogen specific. On the other hand,
the inflammatory response will also be host specific, as the initial
cytokine response will be different in patients with different underlying medical conditions, who have chronic inflammation, or
who are taking medications that may modulate the inflammatory
response. Due to the multiple pathogen and host factors that may
influence the inflammatory response, the initial cellular response
and cytokine pattern is likely to be pathogen and host specific.

3.2

Cytokine profiles

Based on the results of ensemble clustering, Euclidean distance
and Ward’s D linkage metrics were identified as the most clinically
meaningful for our needs. Each heatmap and dendrogram depict
some separation of patients’ inflammatory response. A heatmap
and dendrogram for cytokines in sputum is depicted in Figure 1a.
A heatmap and dendrogram for cytokines in plasma is depicted
in Figure 1b. The cophenetic correlation coefficient comparing
the clustering of patients in plasma and sputum determinations
was 0.14, suggesting low correlation between plasma and sputum clusterings. A heatmap and dendrogram for cytokines in
plasma/sputum ratio is depicted in Figure 1c. In each figure,
a horizontal line was drawn to indicate a suggested separation
of inflammatory response patterns based on the cluster dendrograms and visual inspection of the heatmaps.

4

Discussion

This pilot study suggests that it may be possible to identify distinct
cytokine patterns in plasma and sputum in hospitalized patients
with CAP at the time of hospital admission. We found that approximately half of the patients were in each inflammatory response
group across analysis of sputum cytokines, plasma cytokines, and
the plasma/sputum cytokine ratio. Several patients were retained
in the same group in all 3 analyses. Since this was a pilot study,
larger studies may identify more than the two patterns identified in our study. The only clinically relevant difference identified in the patient characteristics comparisons between high vs
low inflammatory phenotypes was the need for direct ICU admission when comparing both sputum and plasma cytokines. In
both comparisons, patients with lower inflammatory phenotypes
necessitated more intensive care on admission compared to those
with higher inflammatory phenotypes. With our small sample size
it is unclear as to if these differences are real or due to chance
however this may be an interesting variable to evaluate in future
larger studies. For sputum cytokines, it is possible that patients
with a lower inflammatory response on admission have a poor
local immune response and may end with a more severe disease
leading to ICU admission.
A timeline of the inflammatory response in patients with pneumonia can be generalized as follows (Figure 2): At time zero, during
the initial invasion of organisms into the alveolar space, there is

On days two and three post infection, a well-developed lung inflammatory response should be present. The initially specific inflammatory response may begin to evolve into non-specific inflammatory pathways. At this time, the local lung inflammatory
response may spill over into the circulatory system, generating a
systemic inflammatory response.
Patients with pneumonia are hospitalized with an average of 3
to 5 days of signs and symptoms. By this time, we hypothesized
that patients present with two patterns of inflammatory response,
one associated with repair, and another associated with injury, as
depicted in Figure 2. We further hypothesized that these patterns
of response can be identified by performing a cluster analysis of
cytokines at the time of hospital admission. In the current pilot
study, we were able to characterize patterns of local (sputum) and
systemic (plasma) inflammatory response in hospitalized patients
with pneumonia.
We speculate that patients with an exaggerated inflammatory pattern only in the sputum may not be ideal candidates for clinical
trials of immunomodulatory therapies, since a local immune response is an appropriate physiologic response to pneumonia. Reducing a non-exaggerated immune response may not be therapeutic, could bias a trial’s results to the null, and could even lead
to poor outcomes. However, patients with an exaggerated inflammatory response in the circulation may be excellent candidates
for these trials due to their systemic cytokine storm. As depicted
in Figure 2, 8 of the 13 CAP patients in our study appeared to
have an exaggerated inflammatory response in plasma. These patients would be appropriate candidates for immunomodulation.
Since this was a pilot study, we enrolled a limited number of patients. Evaluating only these 13 patients limits the generalizability. Furthermore, this small sample size allows for potentially biased cluster analyses. Another limitation of our study is that the
line separating our definition of the exaggerated inflammatory re-
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Fig. 2 A timeline of the inflammatory response in patients with pneumonia

sponse was partially based on visual inspection of the heatmap.
This may lead to misclassification of some patients due to the
partially subjective nature of this classification. Not all aspects of
inflammation and anti-inflammation were evaluated in this study.
Other makers may be important for determining an exaggerated
inflammatory response to infection. Another limitation is that
the bacterial burden was not measured. This can influence inflammatory response and bias the clustering results. One possible
strength of our study is the ability of the cluster analysis to normalize cytokine values without dependence on a single cytokine
value that may be pro- or anti-inflammatory on its own.

rithms. Results of the analysis could be reported back to a mobile
device in real-time as a yes/no decision rule. This would allow for
rapid determination of the level of inflammation to define candidacy into clinical trials for immunomodulatory therapies.
In conclusion, we were able to define patterns of inflammatory
response using cytokine data in this pilot study. Our results suggest that airway and systemic inflammation in CAP is heterogeneous, providing proof of principle that stratification based on
the inflammatory patterns may be possible for future trials of immunomodulation.

Funding: This study was partially funded by the Division of InThese interesting results suggest a prospective study with a larger
number of patients is warranted, with the goal to characterize
patterns of inflammatory response in blood and sputum in patients with CAP at the time of hospital admission. In this study,
it will be important to evaluate variables that may confound
the inflammatory response such as etiology of CAP, the use of
steroids, and the use of macrolide antibiotics. Furthermore, if cytokine values were to be determined immediately upon admission
each value could be automatically uploaded to and analyzed by a
cloud-based application using supervised machine learning algo-

fectious Diseases. Dr. Restrepo’s time is partially protected by
Award Number K23HL096054 from the National Heart, Lung,
and Blood Institute. The content is solely the responsibility of
the authors and does not necessarily represent the official views
of the National Heart, Lung, And Blood Institute or the National
Institutes of Health nor the Department of Veterans Affairs.

Author Contributions: All authors met ICMJE authorship criteria. TLW, RRK, RFB, WAM, FWA, PP, JB, and JAR conceived
and designed the research plan. RFB conducted the laboratory
ULJRI Vol 1,(1) 2017

3–11 | 8

research. TLW, RRK, WAM, RFB, and JAR conducted the data
analysis. All authors were involved in data interpretation. TLW
and JAR wrote the first draft of the manuscript. All authors critically reviewed the manuscript for important intellectual content.
All authors agree with the manuscript results and conclusions.

9

References
1 C. A. Blum, N. Nigro, M. Briel, P. Schuetz, E. Ullmer,
I. Suter-Widmer, B. Winzeler, R. Bingisser, H. Elsaesser,
D. Drozdov, B. Arici, S. A. Urwyler, J. Refardt, P. Tarr,
S. Wirz, R. Thomann, C. Baumgartner, H. Duplain, D. Burki,
W. Zimmerli, N. Rodondi, B. Mueller, and M. Christ-Crain,
“Adjunct prednisone therapy for patients with communityacquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial,” The Lancet, 2015.
2 M. Confalonieri, R. Urbino, A. Potena, M. Piattella,
P. Parigi, G. Puccio, R. Della Porta, C. Giorgio, F. Blasi,
R. Umberger, and G. U. Meduri, “Hydrocortisone infusion
for severe community-acquired pneumonia: a preliminary
randomized study,” Am J Respir Crit Care Med, vol.
171, no. 3, pp. 242–8, 2005. [Online]. Available: http:
//www.ncbi.nlm.nih.gov/pubmed/15557131
3 S. Fernandez-Serrano,
J. Dorca,
C. Garcia-Vidal,
N. Fernandez-Sabe, J. Carratala, A. Fernandez-Aguera,
M. Corominas, S. Padrones, F. Gudiol, and F. Manresa,
“Effect of corticosteroids on the clinical course of communityacquired pneumonia: a randomized controlled trial,” Crit
Care, vol. 15, no. 2, p. R96, 2011.
4 P. Marik, P. Kraus, J. Sribante, I. Havlik, J. Lipman, and D. W.
Johnson, “Hydrocortisone and tumor necrosis factor in severe
community-acquired pneumonia. a randomized controlled
study,” Chest, vol. 104, no. 2, pp. 389–92, 1993. [Online].
Available: http://www.ncbi.nlm.nih.gov/pubmed/8339624
5 V. U. McHardy and M. E. Schonell, “Ampicillin dosage
and use of prednisolone in treatment of pneumonia:
co-operative controlled trial,” Br Med J, vol. 4, no.
5840, pp. 569–73, 1972. [Online]. Available:
http:
//www.ncbi.nlm.nih.gov/pubmed/4404939
6 S. C. Meijvis, H. Hardeman, H. H. Remmelts, R. Heijligenberg,
G. T. Rijkers, H. van Velzen-Blad, G. P. Voorn, E. M. van de
Garde, H. Endeman, J. C. Grutters, W. J. Bos, and
D. H. Biesma, “Dexamethasone and length of hospital
stay in patients with community-acquired pneumonia: a
randomised, double-blind, placebo-controlled trial,” Lancet,
vol. 377, no. 9782, pp. 2023–30, 2011. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/21636122
7 K. Mikami, M. Suzuki, H. Kitagawa, M. Kawakami, N. Hirota,
H. Yamaguchi, O. Narumoto, Y. Kichikawa, M. Kawai,
H. Tashimo, H. Arai, T. Horiuchi, and Y. Sakamoto,
“Efficacy of corticosteroids in the treatment of communityacquired pneumonia requiring hospitalization,” Lung, vol.
185, no. 5, pp. 249–55, 2007. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/17710485
8 D. Snijders, J. M. Daniels, C. S. de Graaff, T. S. van der Werf,
and W. G. Boersma, “Efficacy of corticosteroids in community-

10

11

12

13

14

15

16

acquired pneumonia - a randomized double blinded clinical
trial,” Am J Respir Crit Care Med, 2010.
J. Wagner, H. N., J. Bennett, I. L., L. Lasagna, L. E.
Cluff, M. B. Rosenthal, and G. S. Mirick, “The effect of
hydrocortisone upon the course of pneumococcal pneumonia
treated with penicillin,” Bull Johns Hopkins Hosp, vol. 98,
no. 3, pp. 197–215, 1956. [Online]. Available: http:
//www.ncbi.nlm.nih.gov/pubmed/13304518
A. Torres, O. Sibila, M. Ferrer, E. Polverino, R. Menendez,
J. Mensa, A. Gabarrus, J. Sellares, M. I. Restrepo,
A. Anzueto, M. S. Niederman, and C. Agusti, “Effect
of corticosteroids on treatment failure among hospitalized
patients with severe community-acquired pneumonia and
high inflammatory response: a randomized clinical trial,”
JAMA, vol. 313, no. 7, pp. 677–86, 2015. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/25688779
V. F. Corrales-Medina and D. M. Musher, “Immunomodulatory agents in the treatment of community-acquired
pneumonia: a systematic review,” J Infect, vol. 63, no. 3,
pp. 187–99, 2011. [Online]. Available:
http://www.
ncbi.nlm.nih.gov/pubmed/21763343http://ac.els-cdn.com/
S0163445311004063/1-s2.0-S0163445311004063-main.
pdf?_tid=4fe56550-f8d1-11e4-b280-00000aab0f26&
acdnat=1431454040_226c865cfc057f893c797bd5e2f0d15a
N. Horita, T. Otsuka, S. Haranaga, H. Namkoong, M. Miki,
N. Miyashita, F. Higa, H. Takahashi, M. Yoshida, S. Kohno,
and T. Kaneko, “Adjunctive systemic corticosteroids for
hospitalized community-acquired pneumonia: Systematic
review and meta-analysis 2015 update,” Sci Rep, vol. 5, p.
14061, 2015. [Online]. Available: http://www.ncbi.nlm.nih.
gov/pmc/articles/PMC4571641/pdf/srep14061.pdf
J. Aspa, O. Rajas, F. Rodriguez de Castro, M. C. Huertas,
L. Borderias, F. J. Cabello, J. Tabara, S. Hernandez-Flix,
A. Martinez-Sanchis, A. Torres, and G. Pneumococcal
Pneumonia in Spain Study, “Impact of initial antibiotic choice
on mortality from pneumococcal pneumonia,” Eur Respir
J, vol. 27, no. 5, pp. 1010–9, 2006. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/16455824
L. M. Baddour, V. L. Yu, K. P. Klugman, C. Feldman,
A. Ortqvist, J. Rello, A. J. Morris, C. M. Luna, D. R. Snydman,
W. C. Ko, M. B. Chedid, D. S. Hui, A. Andremont, C. C. Chiou,
and G. International Pneumococcal Study, “Combination
antibiotic therapy lowers mortality among severely ill
patients with pneumococcal bacteremia,” Am J Respir Crit
Care Med, vol. 170, no. 4, pp. 440–4, 2004. [Online].
Available: http://www.ncbi.nlm.nih.gov/pubmed/15184200
R. Dwyer, A. Ortqvist, E. Aufwerber, B. Henriques Normark,
T. J. Marrie, M. A. Mufson, A. Torres, M. A. Woodhead,
M. Alenius, and M. Kalin, “Addition of a macrolide to a
ss-lactam in bacteremic pneumococcal pneumonia,” Eur J
Clin Microbiol Infect Dis, vol. 25, no. 8, pp. 518–21, 2006.
[Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/
16896822
J. A. Martinez, J. P. Horcajada, M. Almela, F. Marco,
A. Soriano, E. Garcia, M. A. Marco, A. Torres, and

ULJRI Vol 1,(1) 2017

3–11 | 9

17

18

19

20

21

22

23

24

25

J. Mensa, “Addition of a macrolide to a beta-lactam-based
empirical antibiotic regimen is associated with lower inhospital mortality for patients with bacteremic pneumococcal
pneumonia,” Clin Infect Dis, vol. 36, no. 4, pp. 389–95, 2003.
[Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/
12567294
M. A. Mufson and R. J. Stanek, “Revisiting combination antibiotic therapy for community-acquired invasive
streptococcus pneumoniae pneumonia,” Clin Infect Dis,
vol. 42, no. 2, pp. 304–6, 2006. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/16355349
K. Weiss, D. E. Low, L. Cortes, A. Beaupre, R. Gauthier, P. Gregoire, M. Legare, F. Nepveu, D. Thibert, C. Tremblay, and
J. Tremblay, “Clinical characteristics at initial presentation
and impact of dual therapy on the outcome of bacteremic
streptococcus pneumoniae pneumonia in adults,” Can Respir
J, vol. 11, no. 8, pp. 589–93, 2004. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/15611810
J. D. Chalmers, A. Singanayagam, M. P. Murray, and
A. T. Hill, “Prior statin use is associated with improved
outcomes in community-acquired pneumonia,” Am J Med,
vol. 121, no. 11, pp. 1002–1007 e1, 2008. [Online]. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=
Retrieve&db=PubMed&dopt=Citation&list_uids=18954848
I. Douglas, S. Evans, and L. Smeeth, “Effect of statin
treatment on short term mortality after pneumonia episode:
cohort study,” BMJ, vol. 342, p. d1642, 2011. [Online].
Available: http://www.ncbi.nlm.nih.gov/pubmed/21471172
F. J. Frost, H. Petersen, K. Tollestrup, and B. Skipper,
“Influenza and copd mortality protection as pleiotropic,
dose-dependent effects of statins,” Chest, vol. 131, no. 4, pp.
1006–12, 2007. [Online]. Available: http://www.ncbi.nlm.
nih.gov/pubmed/17426203
S. R. Majumdar, F. A. McAlister, D. T. Eurich, R. S.
Padwal, and T. J. Marrie, “Statins and outcomes in
patients admitted to hospital with community acquired
pneumonia: population based prospective cohort study,”
BMJ, vol. 333, no. 7576, p. 999, 2006. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/17060337
E. M. Mortensen, M. J. Pugh, L. A. Copeland, M. I.
Restrepo, J. E. Cornell, A. Anzueto, and J. A. Pugh, “Impact
of statins and angiotensin-converting enzyme inhibitors on
mortality of subjects hospitalised with pneumonia,” Eur
Respir J, vol. 31, no. 3, pp. 611–7, 2008. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/17959631
E. M. Mortensen, M. I. Restrepo, A. Anzueto, and J. Pugh,
“The effect of prior statin use on 30-day mortality for
patients hospitalized with community-acquired pneumonia,”
Respir Res, vol. 6, p. 82, 2005. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/16042797
P. R. Myles, R. B. Hubbard, J. E. Gibson, Z. Pogson,
C. J. Smith, and T. M. McKeever, “The impact of statins,
ace inhibitors and gastric acid suppressants on pneumonia
mortality in a uk general practice population cohort,”
Pharmacoepidemiol Drug Saf, vol. 18, no. 8, pp. 697–703,

26

27

28

29

30

31
32

33

34

2009. [Online]. Available: http://www.ncbi.nlm.nih.gov/
pubmed/19455553
L. A. Polgreen, E. A. Cook, J. M. Brooks, Y. Tang,
and P. M. Polgreen, “Increased statin prescribing does
not lower pneumonia risk,” Clin Infect Dis, vol. 60,
no. 12, pp. 1760–6, 2015. [Online]. Available: http:
//www.ncbi.nlm.nih.gov/pubmed/25759433
R. G. Schlienger, D. S. Fedson, S. S. Jick, H. Jick, and C. R.
Meier, “Statins and the risk of pneumonia: a populationbased, nested case-control study,” Pharmacotherapy, vol. 27,
no. 3, pp. 325–32, 2007. [Online]. Available: http:
//www.ncbi.nlm.nih.gov/pubmed/17316144
R. W. Thomsen, A. Riis, J. B. Kornum, S. Christensen,
S. P. Johnsen, and H. T. Sorensen, “Preadmission use of
statins and outcomes after hospitalization with pneumonia:
population-based cohort study of 29,900 patients,” Arch
Intern Med, vol. 168, no. 19, pp. 2081–7, 2008. [Online].
Available: http://www.ncbi.nlm.nih.gov/pubmed/18955636
S. Yende, E. B. Milbrandt, J. A. Kellum, L. Kong, R. L.
Delude, L. A. Weissfeld, and D. C. Angus, “Understanding the
potential role of statins in pneumonia and sepsis,” Crit Care
Med, vol. 39, no. 8, pp. 1871–8, 2011. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/21516038
R. G. Wunderink, P. F. Laterre, B. Francois, D. Perrotin,
A. Artigas, L. O. Vidal, S. M. Lobo, J. S. Juan, S. C.
Hwang, T. Dugernier, S. LaRosa, X. Wittebole, J. F. Dhainaut,
C. Doig, M. H. Mendelson, C. Zwingelstein, G. Su, and
S. Opal, “Recombinant tissue factor pathway inhibitor in
severe community-acquired pneumonia: a randomized trial,”
Am J Respir Crit Care Med, vol. 183, no. 11, pp. 1561–8,
2011. [Online]. Available: http://www.atsjournals.org/doi/
pdf/10.1164/rccm.201007-1167OC
(2015). [Online]. Available: https://clinicaltrials.gov/ct2/
show/NCT01283009
R. G. Wunderink, “Corticosteroids for severe communityacquired pneumonia:
not for everyone,”
JAMA,
vol. 313, no. 7, pp. 673–4, 2015. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/25688777http:
//jama.jamanetwork.com/data/Journals/JAMA/932761/
jed150005.pdf
C. L. Sprung, D. Annane, D. Keh, R. Moreno, M. Singer,
K. Freivogel, Y. G. Weiss, J. Benbenishty, A. Kalenka,
H. Forst, P. F. Laterre, K. Reinhart, B. H. Cuthbertson,
D. Payen, J. Briegel, and C. S. Group, “Hydrocortisone
therapy for patients with septic shock,” N Engl J Med,
vol. 358, no. 2, pp. 111–24, 2008. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/18184957
R. Fernandez-Botran, S. M. Uriarte, F. W. Arnold,
L. Rodriguez-Hernandez, M. J. Rane, P. Peyrani, T. Wiemken,
R. Kelley, S. Uppatla, R. Cavallazzi, F. Blasi, L. Morlacchi, S. Aliberti, C. Jonsson, J. A. Ramirez, and
J. Bordon, “Contrasting inflammatory responses in severe
and non-severe community-acquired pneumonia,” Inflammation, vol. 37, pp. 1158–1166, 2014. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/24557760

ULJRI Vol 1,(1) 2017

3–11 | 10

35 E. Pizzichini, M. M. Pizzichini, A. Efthimiadis, S. Evans,
M. M. Morris, D. Squillace, G. J. Gleich, J. Dolovich,
and F. E. Hargreave, “Indices of airway inflammation in
induced sputum: reproducibility and validity of cell and
fluid-phase measurements,” Am J Respir Crit Care Med, vol.
154, no. 2 Pt 1, pp. 308–17, 1996. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/8756799
36 2015. [Online]. Available:
http://CRAN.R-project.org/
package=clue

37 2015. [Online]. Available:
package=gplots
38 2015. [Online]. Available:
package=dendextend
39 2015. [Online]. Available:
package=dendextendRcpp
40 2014. [Online]. Available:
package=RColorBrewer

http://CRAN.R-project.org/
http://CRAN.R-project.org/
http://CRAN.R-project.org/
http://CRAN.R-project.org/

ULJRI Vol 1,(1) 2017

3–11 | 11

